nach oben

Current Treatment Options in Neurology

Erschienen in:

01.12.2018 | Movement Disorders (A Videnovic, Section Editor)

Gastrointestinal Dysfunction in Parkinson’s Disease

verfasst von: Ronald F. Pfeiffer, MD

Erschienen in: Current Treatment Options in Neurology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

During the past 25 years, there has been an explosion of information regarding the occurrence of gastrointestinal dysfunction in Parkinson’s disease. In this review, the clinical features of gastrointestinal dysfunction in Parkinson’s disease will be described and information regarding the potential role of the enteric nervous system and the gut microbiome in the genesis of Parkinson’s disease will be addressed.

Recent findings

Recognition is growing regarding the role that gastroparesis and small intestinal dysfunction may play in Parkinson’s disease, especially with regard to erratic responses to anti-Parkinson medication. The presence of enteric nervous system involvement in Parkinson’s disease is now well established, but whether the enteric nervous system is the starting point for Parkinson’s disease pathology remains a source of debate. The potential role of the gut microbiome also is beginning to emerge.

Summary

Gastrointestinal dysfunction is a prominent nonmotor feature of Parkinson’s disease and dysfunction can be found along the entire length of the gastrointestinal tract. The enteric nervous system is clearly involved in Parkinson’s disease. Whether it is the initial source of pathology is still a source of controversy. There also is growing recognition of the role that the gut microbiome may play in Parkinson’s disease, but much more research is needed to fully assess this aspect of the disorder.

• Parkinson J. An essay on the shaking palsy. London: Whittingham and Rowland for Sherwood, Neely, and Jones; 1817. A classic treatise that should be read by all neurologists.

Eadie MJ, Tyrer JH. Alimentary disorder in parkinsonism. Australas Ann Med. 1965;14:13–22.PubMed

Edwards LL, Pfeiffer RF, Quigley EMM, Hofman R, Baluff M. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord. 1991;6(2):151–6.PubMed

Edwards LL, Quigley EM, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology. 1992;42(4):726–32.PubMed

Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80(3):276–81.PubMedPubMedCentral

Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14(6):625–39.PubMed

Bagheri H, Damase-Michel C, Lapeyre-Mestre M, Cismondo S, O’Connell D, Senard JM, et al. A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol. 1999;22(4):213–5.PubMed

Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord. 2002;17(6):1318–20.PubMed

Narayanaswami P, Geisbush T, Tarulli A, Raynor E, Gautam S, Tarsy D, et al. Drooling in Parkinson’s disease: a randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins. Parkinsonism Relat Disord. 2016;30:73–7.PubMed

10.

Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:10–5.PubMed

11.

Takizawa C, Gemmell E, Kenworthy J, Speyer R. A systematic review of the prevalence of oropharyngeal dysphagia in stroke, Parkinson’s disease, Alzheimer’s disease, head injury, and pneumonia. Dysphagia. 2016;31(3):434–41.PubMed

12.

Pflug C, Bihler M, Emich K, Niessen A, Nienstedt JC, Flügel T, et al. Critical dysphagia is common in Parkinson disease and occurs even in early stages: a prospective cohort study. Dysphagia. 2018;33(1):41–50.PubMed

13.

Mu L, Sobotka S, Chen J, Su H, Sanders I, Nvirenda T, et al. Parkinson disease affects peripheral sensory nerves in the pharynx. J Neuropathol Exp Neurol. 2013;72(7):614–23.PubMedPubMedCentral

14.

Byrne KG, Pfeiffer R, Quigley EM. Gastrointestinal dysfunction in Parkinson’s disease. A report of clinical experience at a single center. J Clin Gastroenterol. 1994;19(1):11–6.PubMed

15.

Born LJ, Harned RH, Rikkers LF, Pfeiffer RF, Quigley EMM. Cricopharyngeal dysfunction in Parkinson’s disease: role in dysphagia and response to myotomy. Mov Disord. 1996;11(1):53–8.PubMed

16.

Stroudley J, Walsh M. Radiological assessment of dysphagia in Parkinson’s disease. Br J Radiol. 1991;64(766):890–3.PubMed

17.

Nagaya M, Kachi T, Yamada T, Igata A. Videofluorographic study of swallowing in Parkinson’s disease. Dysphagia. 1998;13(2):95–100.PubMed

18.

Melo A, Monteiro L. Swallowing improvement after levodopa treatment in idiopathic Parkinson’s disease: lack of evidence. Parkinsonism Relat Disord. 2013;19(3):279–81.PubMed

19.

Sutton JP. Dysphagia in Parkinson’s disease is responsive to levodopa. Parkinsonism Relat Disord. 2013;19(3):282–4.PubMed

20.

Warnecke T, Suttrup I, Schröder JB, Osada N, Oelenberg S, Hamacher C, et al. Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability testing of the FEES-levodopa-test. Parkinsonism Relat Disord. 2016;28:100–6.PubMed

21.

Fosso CL, Quigley EMM. A critical review of the current clinical landscape of gastroparesis. Gastroenterol Hepatol (NY). 2018;14(3):140–5.

22.

Goetze O, Wieczorek J, Mueller T, Przuntek H, Schmidt WE, Woitalla D. Impaired gastric emptying of a solid test meal in patients with Parkinson’s disease using ¹³C-sodium octanoate breath test. Neurosci Lett. 2005;375(3):170–3.PubMed

23.

Tanaka Y, Kato T, Nishida H, Yamada M, Koumura A, Sakurai T, et al. Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson’s disease? An analysis using the 13C-acetate breath test. J Neurol. 2011;258(3):421–6.PubMed

24.

Heetun ZS, Quigley EM. Gastroparesis and Parkinson’s disease: a systematic review. Parkinsonism Relat Disord. 2012;18(5):433–40.PubMed

25.

Su A, Gandhy R, Barlow C, Triadafilopoulos G. Utility of the wireless motility capsule and lactulose breath testing in the evaluation of patients with Parkinson’s disease who present with functional gastrointestinal symptoms. BMJ Open Gastro. 2017;4(1):e000132.

26.

Hasler WL, May KP, Wilson LA, Van Natta M, Parkman HP, Pasricha PJ, et al. Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. Neurogastroenterol Motil. 2018; 30(2). https://doi.org/10.1111/nmo.13196.

27.

Fasano A, Bove F, Gabrielli M, Petracca M, Zocco MA, Ragazzoni E, et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord. 2013;28(9):1241–9.PubMed

28.

Sato H, Yamamoto T, Sato M, Furusawa Y, Murata M. Dysphagia causes symptom fluctuations after oral L-DOPA treatment in a patient with Parkinson disease. Case Rep Neurol. 2018;10(1):101–7.PubMedPubMedCentral

29.

Staisch J, Bakis G, Nutt J. A wrinkle in ON-time – a GI structural abnormality confounding levodopa therapy with Duopa rescue; a case study. Parkinsonism Relat Disord. 2018;50:130–1.PubMed

30.

Doi H, Sakakibara R, Sato M, Hirai S, Masaka T, Kishi M, et al. Nizatidine ameliorates gastroparesis in Parkinson’s disease: a pilot study. Mov Disord. 2014;29(4):562–6.PubMed

31.

Chedid V, Camilleri M. Relamorelin for the treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2017;26(10):1189–97.PubMed

32.

Gil RA, Hwynn N, Fabian T, Joseph S, Fernandez HH. Botulinum toxin type A for the treatment of gastroparesis in Parkinson’s disease patients. Parkinsonism Relat Disord. 2011;17(4):285–7.PubMed

33.

Triadafilopoulos G, Gandhy R, Barlow C. Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson’s disease. Parkinsonism Relat Disord. 2017;44:33–7.PubMed

34.

Shada A, Nielsen A, Marowski S, Helm M, Funk LM, Kastenmeier A, et al. Wisconsin’s Enterra therapy experience: a multi-institutional review of gastric electrical stimulation for medically refractory gastroparesis. Surgery 2018; https://doi.org/10.1016/j.surg.2018.04.043.PubMed

35.

Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord. 2011;26(5):889–92.PubMed

36.

Tan AH, Mahadeva S, Thalha AM, Gibson PR, Kiew CK, Yeat CM, et al. Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20(5):535–40.PubMed

37.

Jost WH, Schimrigk K. Constipation in Parkinson’s disease. Klin Wochenschr. 1991;69(20):906–9.PubMed

38.

Edwards LL, Quigley EMM, Harned RK, Hofman R, Pfeiffer RF. Characterization of swallowing and defecation in Parkinson’s disease. Am J Gastroenterol. 1994;89(1):15–25.PubMed

39.

Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EMM. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord. 1997;12(6):946–51.PubMed

40.

Knudsen K, Federova TD, Bekker AC, Iversen P, Østergaard K, Krogh K, et al. Objective colonic dysfunction is far more prevalent than subjective constipation in Parkinson’s disease: a colon transit and volume study. J Parkinsons Dis. 2017;7(2):359–67.PubMed

41.

Parkinson Study Group. A randomized trial of relamorelin for constipation in Parkinson’s disease (MOVE-PD): trial results and lessons learned. Parkinsonism Relat Disord. 2017;37:101–5.

42.

Zesiewicz TA, Sullivan KL, Arnulf I, Chaudhuri KR, Morgan JC, Gronseth GS, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease. Neurology. 2010;74(11):924–31.PubMed

43.

Ondo WG, Kenney C, Sullivan K, Davidson A, Hunter C, Jahan I, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78(21):1650–4.PubMed

44.

Ron Y, Halpern Z, Safadi R, Dickman R, Dekel R, Sperber AD. Safety and efficacy of the vibrating capsule, an innovative non-pharmacological treatment modality for chronic constipation. Neurogastroenterol Motil. 2015;27(1):99–104.PubMed

45.

Bassotti G, Maggio D, Battaglia E, Giulietti O, Spinozzi F, Reboldi G, et al. Manometric investigation of anorectal function in early and late stage Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000;68(6):768–70.PubMedPubMedCentral

46.

Sun WM, Rao SS. Manometric assessment of anorectal function. Gastroenterol Clin N Am. 2001;30(1):15–32.

47.

Mathers SE, Kempster PA, Law PJ, Frankel JP, Bartram CI, Lees AJ, et al. Anal sphincter dysfunction in Parkinson’s disease. Arch Neurol. 1989;46(10):1061–4.PubMed

48.

Edwards LL, Quigley EM, Harned RK, Hofman R, Pfeiffer RF. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol. 1993;33(5):490–3.PubMed

49.

Ashraf W, Pfeiffer RF, Quigley EM. Anorectal manometry in the assessment of anorectal function in Parkinson’s disease: a comparison with chronic idiopathic constipation. Mov Disord. 1994;9(6):655–63.PubMed

50.

Albanese A, Maria G, Bentivoglio AR, Brisinda G, Cassetta E, Tonali P. Severe constipation in Parkinson’s disease relieved by botulinum toxin. Mov Disord. 1997;12(5):764–6.PubMed

51.

Albanese A, Brisinda G, Bentivoglio AR, Maria G. Treatment of outlet obstruction constipation in Parkinson’s disease with botulinum neurotoxin A. Am J Gastroenterol. 2003;98(6):1439–40.PubMed

52.

Qualman SJ, Haupt HM, Yang P, Hamilton SR. Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson’s disease. Gastroenterology. 1984;87(4):848–56.PubMed

53.

Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology. 1987;37(7):1253–5.PubMed

54.

Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathol. 1988;76(3):217–21.PubMed

55.

Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol. 1990;79(6):581–3.PubMed

56.

Singaram C, Ashraf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R, et al. Dopaminergic defect of enteric nervous system in Parkinson’s disease patients with chronic constipation. Lancet. 1995;346(8979):861–4.PubMed

57.

• Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett. 2006;396(1):67–72 Genesis for much of the current discussion of whether PD begins in the gut.PubMed

58.

Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001;57(3):456–62.PubMed

59.

Ueki A, Otsuka M. Life style risks of Parkinson’s disease: association between decreased water intake and constipation. J Neurol. 2004;251(Suppl 7):VII18–23.PubMed

60.

Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pederson L, Borghammer P, et al. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol. 2015;78(4):522–9.PubMed

61.

Liu SY, Chan P, Stoessl AJ. The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system. Transl Neurodegener. 2017;6:4.PubMedPubMedCentral

62.

Lebouvier T, Chaumette T, Damier P, Coron E, Touchefeu Y, Vrignaud S, et al. Pathological lesions in colonic biopsies during Parkinson’s disease. Gut. 2008;57(12):1741–3.PubMed

63.

Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, et al. Alpha-synuclein in colonic submucosa in early untreated Parkinson’s disease. Mov Disord. 2012;27(6):709–15.PubMed

64.

Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases. Mov Disord. 2012;27(6):716–9.PubMed

65.

Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, et al. Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. Acta Neuropathol. 2014;127(2):235–41.PubMed

66.

Forsyth CB, Shannon KM, Kordower JH, Voigt RM, Shaikh M, Jaglin JA, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS One. 2011;6(12):e28032.PubMedPubMedCentral

67.

Clairembault T, Leclair-Visonneau L, Coron E, Bourreille A, Le Dily S, Vavasseur F, et al. Structural alterations of the intestinal epithelial barrier in Parkinson’s disease. Acta Neuropathol Commun. 2015;3:12. https://doi.org/10.1186/s40478-015-0196.

68.

Olanow CW, Prusiner SB. Is Parkinson’s disease a prion disorder? Proc Natl Acad Sci U S A. 2009;106(31):12571–2.PubMedPubMedCentral

69.

Killinger BA, Labrie V. Vertebrate food products as a potential source of prion-like α-synuclein. NPJ Parkinsons Dis. 2017;3:33.PubMedPubMedCentral

70.

Borghammer P. How does Parkinson’s disease begin? Perspectives on neuroanatomical pathways, prions, and histology. Mov Disord. 2018;33(1):48–57.PubMed

71.

Liddle RA. Parkinson’s disease from the gut. Brain Res. 2018;1693(Pt B):201–6.PubMed

72.

Lionnet A, Leclair-Visonneau L, Neunlist M, Murayama S, Takao M, Adler CH, et al. Does Parkinson’s disease start in the gut? Acta Neuropathol. 2018;135(1):1–12.PubMed

73.

•• Adler CH, Beach TG. Neuropathological basis of non-motor manifestations of Parkinson’s disease. Mov Disord. 2016;31(8):1114–9 Superb balanced review of the role of ENS involvement in PD.PubMedPubMedCentral

74.

Annerino DM, Arshad S, Taylor GM, Adler CH, Beach TG, Greene JG. Parkinson’s disease is not associated with gastrointestinal myenteric ganglion neuron loss. Acta Neuropathol. 2012;124(5):665–80.PubMedPubMedCentral

75.

Tysnes OB, Kenborg L, Herlofson K, Steding-Jessen M, Horn A, Olsen JH, et al. Does vagotomy reduce the risk of Parkinson’s disease? Ann Neurol. 2015;78(6):1011–2.PubMed

76.

Tasselli M, Chaumette T, Paillusson S, Monnet Y, Lafoux A, Huchet-Caddiou C, et al. Effects of oral administration of rotenone on gastrointestinal functions in mice. Neurogastroenterol Motil. 2013;25(3):e183–93.PubMed

77.

Zheng LF, Song J, Fan RF, Chen CL, Ren QZ, Zhang XL, et al. The role of the vagal pathway and gastric dopamine in the gastroparesis of rats after a 6-hydroxydopamine microinjection in the substantia nigra. Acta Physiol (Oxf). 2014;211(2):434–46.

78.

Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, et al. Colonic bacterial composition in Parkinson’s disease. Mov Disord. 2015;30(10):1351–60.PubMed

79.

Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015;30(3):350–8.PubMed

80.

Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bὕrmann J, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66–72.PubMed

81.

Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, et al. Parkinson’s disease and PD medications have distinct signatures of the gut microbiome. Mov Disord. 2017;32(5):739–49.PubMedPubMedCentral

82.

Quigley EMM. Microbiota-brain-gut axis and neurodegenerative diseases. Curr Neurol Neurosci Rep. 2017;17(12):94.PubMed

83.

• Quigley EMM. Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet? Nat Rev Gastroenterol Hepatol. 2017;14(5):315–20 Excellent discussion of what is known about the gut microbiome.PubMed

84.

•• Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2016;167(6):1469–80 Elegant, innovative, thought-provoking research study.PubMedPubMedCentral

Titel: Gastrointestinal Dysfunction in Parkinson’s Disease
verfasst von: Ronald F. Pfeiffer, MD
Publikationsdatum: 01.12.2018
Verlag: Springer US
Erschienen in: Current Treatment Options in Neurology / Ausgabe 12/2018
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-018-0539-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of review

Recent findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2018

Current Treatment Strategies and Future Treatment Options for Dravet Syndrome

Cognitive Deficits in Multiple Sclerosis: Recent Advances in Treatment and Neurorehabilitation

Restless Legs Syndrome and Other Movement Disorders of Sleep—Treatment Update

Treatment of Persistent Postural-Perceptual Dizziness (PPPD) and Related Disorders